Leukaemia (all subtypes combined) mortality statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Deaths

Deaths from leukaemia, 2015-2017, UK.

Proportion of all deaths

Percentage leukaemia contributes to total cancer deaths, 2015-2017, UK

Age

Peak mortality rate for leukaemia, 2015-2017, UK

Trend over time

Leukaemia mortality rates have changed differently for each sex since the early 1970s, UK

 

Leukaemia is the 12th most common cause of cancer death in the UK, accounting for 3% of all cancer deaths (2017).[1-3]

In females in the UK, leukaemia is the 12th most common cause of cancer death (3% of all female cancer deaths). In males in the UK it is the 11th most common cause of cancer death (3% of all male cancer deaths).

41% of leukaemia deaths in the UK are in females, and 59% are in males.

Leukaemia mortality rates (European age-standardised (AS) rates) Open a glossary item for persons are significantly lower than the UK average in Northern Ireland, and similar to the UK average in all other UK constituent countries.

Leukaemia (C91-C95), Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Deaths 1,653 148 97 44 1,942
Crude Rate 5.9 5.3 6.1 4.6 5.8
AS Rate 5.7 5.0 5.3 4.8 5.6
AS Rate - 95% LCL 5.4 4.2 4.2 3.4 5.3
AS Rate - 95% UCL 5.9 5.8 6.3 6.3 5.8
Male Deaths 2,411 233 144 51 2,839
Crude Rate 8.8 8.8 9.3 5.5 8.7
AS Rate 10.6 10.4 10.0 7.7 10.4
AS Rate - 95% LCL 10.1 9.0 8.4 5.6 10.1
AS Rate - 95% UCL 11.0 11.7 11.6 9.8 10.8
Persons Deaths 4,064 381 241 95 4,781
Crude Rate 7.3 7.0 7.7 5.1 7.2
AS Rate 7.8 7.3 7.5 6.0 7.7
AS Rate - 95% LCL 7.6 6.6 6.5 4.8 7.5
AS Rate - 95% UCL 8.0 8.0 8.4 7.2 7.9

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item 

For leukaemia mortality differences between countries largely reflect differences in incidence.

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C91-C95.

The term leukaemia describes four main subtypes, acute lymphoblastic leukaemia (ALL), chronic lymphoblastic leukaemia (CLL), acute myeloid leukaemia (CML) and chronic myeloid leukaemia (CML), as well as a number of less common types. It is important to recognise the variation between these subtypes when interpreting statistics on leukaemia as a whole.

Last reviewed:

Leukaemia mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2015-2017, on average each year around 6 in 10 (59%) deaths were in people aged 75 and over.[1-3] This largely reflects higher incidence and lower survival for leukaemia in older people.

Age-specific mortality rates rise steeply from around age 60-64. The highest rates are in the 90+ age group for females and males. Mortality rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 75 to 79,when the age-specific mortality rate is 2 times lower in females than in males.

Leukaemia (C91-C95), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Population, UK, 2015-2017

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, ICD-10 C91-C95.

The term leukaemia describes four main subtypes, acute lymphoblastic leukaemia (ALL), chronic lymphoblastic leukaemia (CLL), acute myeloid leukaemia (CML) and chronic myeloid leukaemia (CML), as well as a number of less common types. It is important to recognise the variation between these subtypes when interpreting statistics on leukaemia as a whole.

Last reviewed:

Leukaemia European age-standardised (AS Open a glossary item) mortality rates for females and males combined remained stable in the UK between 1971-1973 and 2015-2017.[1-3] The change varied markedly between sexes.

For females, leukaemia AS mortality rates in the UK decreased by 10% between 1971-1973 and 2015-2017. For males, leukaemia AS mortality rates in the UK remained stable between 1971-1973 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), leukaemia AS mortality rates for females and males combined decreased by 7%. In females AS mortality rates decreased by 8%, and in males rates decreased by 9%.

Leukaemia (C91-C95), European Age-Standardised Mortality Rates per 100,000 Population, UK, 1971-2017

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Leukaemia mortality rates have decreased overall in some broad age groups in females and males combined in the UK since the early 1970s, but have increased in others.[1-3] Rates in 0-24s have decreased by 78%, in 25-49s have decreased by 65%, in 50-59s have decreased by 53%, in 60-69s have decreased by 19%, in 70-79s have increased by 13%, and in 80+s have increased by 69%.

Leukaemia (C91-C95), European Age-Standardised Mortality Rates per 100,000 Population, By Age, UK, 1971-2017

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

See also

Data is for UK, 1971-2017, C91-C95.

The term leukaemia describes four main subtypes, acute lymphoblastic leukaemia (ALL), chronic lymphoblastic leukaemia (CLL), acute myeloid leukaemia (CML) and chronic myeloid leukaemia (CML), as well as a number of less common types. It is important to recognise the variation between these subtypes when interpreting statistics on leukaemia as a whole.

Last reviewed:

Leukaemia mortality rates are projected to fall by 18% in the UK between 2014 and 2035, to 8 deaths per 100,000 people by 2035.[1] This includes a larger decrease for males than for females.

For males, leukaemia European age-standardised (AS) Open a glossary item mortality rates in the UK are projected to fall by 22% between 2014 and 2035, to 10 deaths per 100,000 by 2035.[1] For females, rates are projected to fall by 15% between 2014 and 2035, to 6 deaths per 100,000 by 2035.[1]

Leukaemia (C91-C95), Observed and Projected Age-Standardised Mortality Rates, by Sex, UK, 1979-2035

 

It is projected that 6,091 deaths from leukaemia (3,552 in males, 2,539 in females) will occur in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C91-C95

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.